Association Between Medication Adherence and 1-Year Major Cardiovascular Adverse Events After Acute Myocardial Infarction in China

Pu Shang, Gordon G Liu, Xin Zheng, P Michael Ho, Shuang Hu, Jing Li, Zihan Jiang, Xi Li, Xueke Bai, Yan Gao, Chao Xing, Yun Wang, Sharon-Lise Normand, Harlan M Krumholz, Pu Shang, Gordon G Liu, Xin Zheng, P Michael Ho, Shuang Hu, Jing Li, Zihan Jiang, Xi Li, Xueke Bai, Yan Gao, Chao Xing, Yun Wang, Sharon-Lise Normand, Harlan M Krumholz

Abstract

Background Secondary prevention after acute myocardial infarction ( AMI ) requires long-term guideline-directed medical therapy. However, the level of medication adherence, factors associated with poor adherence, and extent to which good adherence can reduce adverse events after AMI in China remain uncertain. Methods and Results In 2013 to 2014, 4001 AMI patients aged ≥18 years were discharged alive from 53 hospitals across China (mean age 60.5±11.7 years; 22.7% female). Good adherence was defined as taking medications (aspirin, β-blockers, statins, clopidogrel, or angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers) ≥90% of the time as prescribed. Cox models assessed the association between good adherence (a time-varying covariate) and 1-year cardiovascular events after AMI . The most common medications were aspirin (82.2%) and statins (80.5%). There were 243 patients who were not prescribed any medications during follow-up; 1-year event rates were higher for these patients (25.1%, 95% CI 19.7-30.6%) versus those taking ≥1 medications (6.6%, 95% CI 5.76-7.34%). The overall rate of good adherence was 52.9%. Good adherence was associated with lower risk of 1-year events (adjusted hazard ratio 0.61, 95% CI 0.49-0.77). The most common reason for poor adherence was belief that one's condition had improved/no longer required medication. More comorbidities and lower education level were associated with poor adherence. Conclusions Good adherence reduced 1-year cardiovascular event risk after AMI . About half of our cohort did not have good adherence. National efforts to improve AMI outcomes in China should focus on medication adherence and educating patients on the importance of cardiovascular medications for reducing risk of recurrent events. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT01624909.

Keywords: acute myocardial infarction; cardiovascular adverse events; medication adherence; patient‐reported outcomes.

Figures

Figure 1
Figure 1
Distribution of prescribed medications over the study period. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin‐receptor blocker.
Figure 2
Figure 2
Number of prescribed medications per patient over the study period.
Figure 3
Figure 3
Kaplan–Meier estimator to show the observed probability of being free from 1‐year major cardiovascular adverse events in the good adherence (score ≥0.90), poor adherence (score

Figure 4

Reasons for not taking medications…

Figure 4

Reasons for not taking medications as prescribed by interview period (top panel: 1…

Figure 4
Reasons for not taking medications as prescribed by interview period (top panel: 1 month after discharge, middle panel: 6 months after discharge, and bottom panel: 12 months after discharge). The most frequently reported reason for patients not taking medications as prescribed was, “I think that my condition has improved and do not need to take it.” The proportion of patients reporting this reason increased over time. Take β‐blocker for example; the percentage of patients reporting this reason was 27.4% at 1 month, 42.1% at 6 months, and 45.8% at 12 months. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin‐receptor blocker.
Figure 4
Figure 4
Reasons for not taking medications as prescribed by interview period (top panel: 1 month after discharge, middle panel: 6 months after discharge, and bottom panel: 12 months after discharge). The most frequently reported reason for patients not taking medications as prescribed was, “I think that my condition has improved and do not need to take it.” The proportion of patients reporting this reason increased over time. Take β‐blocker for example; the percentage of patients reporting this reason was 27.4% at 1 month, 42.1% at 6 months, and 45.8% at 12 months. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin‐receptor blocker.

References

    1. Chaudhry SI, Khan RF, Chen J, Dharmarajan K, Dodson JA, Masoudi FA, Wang Y, Krumholz HM. National trends in recurrent AMI hospitalizations 1 year after acute myocardial infarction in Medicare beneficiaries: 1999–2010. J Am Heart Assoc. 2014;3:e001197 DOI: 10.1161/JAHA.114.001197.
    1. Wang Y, Lichtman JH, Dharmarajan K, Masoudi FA, Ross JS, Dodson JA, Chen J, Spertus JA, Chaudhry SI, Nallamothu BK, Krumholz HM. National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010. Am Heart J. 2015;169:78–85.
    1. Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: mechanisms, incidence and identification of patients at risk. World J Cardiol. 2017;9:407–415.
    1. Sampson UK, Pfeffer MA, McMurray JJ, Lokhnygina Y, White HD, Solomon SD. Predictors of stroke in high‐risk patients after acute myocardial infarction: insights from the VALIANT Trial. Eur Heart J. 2007;28:685–691.
    1. Tu JV, Austin PC, Walld R, Roos L, Agras J, Mcdonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol. 2001;37:992–997.
    1. Jneid H, Addison D, Bhatt DL, Fonarow GC, Gokak S, Grady KL, Green LA, Heidenreich PA, Ho PM, Jurgens CY, King ML, Kumbhani DJ, Pancholy S. 2017 AHA/ACC clinical performance and quality measures for adults with ST‐elevation and non‐ST‐elevation myocardial infarction. J Am Coll Cardiol. 2017;70:2048–2090.
    1. Kim S, Shin DW, Yun JM, Hwang Y, Park SK, Ko YJ, Cho B. Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension. 2016;67:506–512.
    1. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta‐analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
    1. Yang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease among older adults: a population‐based cohort study. J Am Heart Assoc. 2017;6:e006056 DOI: 10.1161/JAHA.117.006056.
    1. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence‐based pharmacotherapy and long‐term mortality after acute myocardial infarction. JAMA. 2007;297:177–186.
    1. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78:684–698.
    1. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Hoffman E, Goto S, Ohman EM, Bhatt DL; REduction of Atherothrombosis for Continued Health Registry Investigators . Adherence to secondary prevention medications and four‐year outcomes in outpatients with atherosclerosis. Am J Med. 2013;126:693–700.e1.
    1. Kuepper‐Nybelen J, Hellmich M, Abbas S, Ihle P, Griebenow R, Schubert I. Association of long‐term adherence to evidence‐based combination drug therapy after acute myocardial infarction with all‐cause mortality. A prospective cohort study based on claims data. Eur J Clin Pharmacol. 2012;68:1451–1460.
    1. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304–314.
    1. Han X, Zhou F, Li H, Xing X, Chen L, Wang Y, Zhang C, Liu X, Suo L, Wang J, Yu G, Wang G, Yao X, Yu H, Wang L, Liu M, Xue C, Liu B, Zhu X, Li Y, Xiao Y, Cui X, Li L, Purdy JE, Cao B; CAP‐China Network . Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community‐acquired pneumonia. BMC Infect Dis. 2018;18:192.
    1. Kipsang J, Chen J, Tang C, Li X, Wang H. Self reported adherence to antiretroviral treatment and correlates in Hunan province, the Peoples Republic of China. Int J Nurs Sci. 2018;5:162–167.
    1. Wei L, Champman S, Li X, Li X, Li S, Chen R, Bo N, Chater A, Horne R. Beliefs about medicines and non‐adherence in patients with stroke, diabetes mellitus and rheumatoid arthritis: a cross‐sectional study in China. BMJ Open. 2017;7:e017293.
    1. Yue Z, Bin W, Weilin Q, Aifang Y. Effect of medication adherence on blood pressure control and risk factors for antihypertensive medication adherence. J Eval Clin Pract. 2015;21:166–172.
    1. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124–1134.
    1. Group WB . Toward a healthy and harmonious life in China: stemming the rising tide of non‐communicable diseases. 2011. Available at: . Accessed March 27, 2014.
    1. Li J, Dreyer RP, Li X, Du X, Downing NS, Li L, Zhang HB, Feng F, Guan WC, Xu X, Li SX, Lin ZQ, Masoudi FA, Spertus JA, Krumholz HM, Jiang LX; China PEACE Collaborative Group . China patient‐centered evaluative assessment of cardiac events prospective study of acute myocardial infarction: study design. Chin Med J (Engl). 2016;129:72–80.
    1. Wang Y, Li J, Zheng X, Jiang ZH, Hu S, Wadhera RK, Bai XK, Lu JP, Wang QY, Li YT, Wu CQ, Xing C, Normand S‐L, Krumholz HM, Jiang LX. Risk factors associated with major cardiovascular events 1 year after acute myocardial infarction. JAMA Netw Open. 2018;1:e181079.
    1. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
    1. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88:229–233.
    1. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut‐point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303–2310.
    1. Liu HX, Gao W, Zhao D, Shang JJ. Survey on the hospitalization treatment status of acute myocardial infarction patients in 13 hospitals of western medicine and traditional Chinese medicine in Beijing. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38:306–310.
    1. Wang Y, Fu R, Wang Z, Bao H, Chen Y, Yang F, Luo X, Liu M. Assessing the quality of care for patients with acute myocardial infarction in China. Clin Cardiol. 2015;38:327–332.

Source: PubMed

3
Subscribe